Celldex Therapeutics (CLDX) News Today $21.26 +0.91 (+4.47%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$20.98 -0.28 (-1.32%) As of 06/13/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why is Celldex Therapeutics Up Today?Celldex Therapeutics, Inc. (CLDX) shares are rising as investors react to a string of positive clinical updates on barzolvolimab, strong market momentum, and renewed analyst support. Barzolvolimab demonstrated robust efficacy in urticaria patients, boosting confidence in its therapeutic potential (The Pharma Letter). Impressive skin disorder trial data drove a noticeable share jump, underscoring strength in Celldex’s immunology pipeline (Investing.com). The stock traded up by approximately 9% following the latest news flow, reflecting heightened investor interest (MarketBeat). HC Wainwright reaffirmed its “buy” rating and set a $50 price target—implying over 135% upside from current levels (MarketBeat/Benzinga). New Phase 2 data presented at EAACI showed unprecedented 76-week complete responses and quality-of-life improvements in chronic spontaneous urticaria (GlobeNewswire). GuruFocus highlighted promising Phase 2 results in chronic spontaneous urticaria, reinforcing confidence in barzolvolimab’s long-term prospects. A Benzinga survey of eight analysts offered a broad range of projections for Celldex’s future, indicating varied market expectations. Cantor Fitzgerald lowered its FY2026 EPS estimate to –$4.68 (versus a –$2.48 consensus), signaling deeper projected losses ahead (AmericanBankingNews). Posted 1+ days agoAI Generated. May Contain Errors. CLDX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025June 14 at 10:48 AM | globenewswire.comCelldex shares jump on impressive skin disorder drug dataJune 13 at 2:05 PM | in.investing.comCelldex Therapeutics (NASDAQ:CLDX) Trading Up 9% - Here's WhyCelldex Therapeutics (NASDAQ:CLDX) Trading 9% Higher - Time to Buy?June 13 at 1:27 PM | marketbeat.comForecasting The Future: 8 Analyst Projections For Celldex TherapeuticsJune 13 at 9:00 AM | benzinga.comCelldex Therapeutics' (CLDX) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Celldex Therapeutics in a report on Friday.June 13 at 8:16 AM | marketbeat.comCelldex Therapeutics Inc (CLDX) Reports Promising Phase 2 Results for Barzolvolimab in Chronic ...June 12 at 10:36 PM | gurufocus.comCelldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025June 12 at 6:01 PM | globenewswire.comBrokers Set Expectations for CLDX FY2026 EarningsJune 12 at 3:03 AM | americanbankingnews.comCelldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 CongressJune 10, 2025 | globenewswire.comEquities Analysts Issue Forecasts for CLDX FY2026 EarningsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Celldex Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaJune 10, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Trading Down 4.5% - Should You Sell?Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 4.5% - What's Next?June 9, 2025 | marketbeat.comTwo Sigma Investments LP Buys Shares of 33,025 Celldex Therapeutics, Inc. (NASDAQ:CLDX)Two Sigma Investments LP bought a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 33,025 shares of the biopharmaceutical company's stock, valued atJune 7, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Bank of America Corp DEBank of America Corp DE cut its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 80.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,848 shares of the biopharmaceutical company's stock aJune 7, 2025 | marketbeat.comCelldex Approves Equity Plan Amendment and Elects New DirectorJune 6, 2025 | tipranks.comCelldex Therapeutics Announces Election of Denice Torres to its Board of DirectorsJune 6, 2025 | globenewswire.comApella Capital LLC Invests $309,000 in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Apella Capital LLC purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 17,000 shares of the biopharmaceutical comJune 6, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 13.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor ownJune 6, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume - Here's WhyCelldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume - What's Next?June 4, 2025 | marketbeat.comMillennium Management LLC Has $2.37 Million Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Millennium Management LLC trimmed its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 19.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 93,602 shares of the biopharmaceutical companyJune 2, 2025 | marketbeat.comNuveen Asset Management LLC Sells 75,257 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Nuveen Asset Management LLC cut its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 20.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 288,378 shares of the biopharmaceutical company's stock after selliMay 31, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Stock Price Up 6.6% - Time to Buy?Celldex Therapeutics (NASDAQ:CLDX) Trading Up 6.6% - Here's WhyMay 30, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Stock Price Down 3.5% - Should You Sell?Celldex Therapeutics (NASDAQ:CLDX) Trading Down 3.5% - Should You Sell?May 29, 2025 | marketbeat.comPolar Asset Management Partners Inc. Grows Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Polar Asset Management Partners Inc. grew its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 1,318.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 137,550 shares of the biopharmaceutical company's stocMay 28, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Rating of "Moderate Buy" by AnalystsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, seven have issued a buy reMay 28, 2025 | marketbeat.comTFG Asset Management GP Ltd Invests $4.85 Million in Celldex Therapeutics, Inc. (NASDAQ:CLDX)TFG Asset Management GP Ltd bought a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 192,000 shares of the biopharmacMay 27, 2025 | marketbeat.comCelldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growthMay 24, 2025 | investing.comTwinbeech Capital LP Reduces Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Twinbeech Capital LP lowered its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 75.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 34,558 shares of the biopharmaceutical company's stock after selling 105,944 sharesMay 24, 2025 | marketbeat.comDeutsche Bank AG Acquires 82,042 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Deutsche Bank AG lifted its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 207.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 121,501 shares of the biopharmaceuticaMay 23, 2025 | marketbeat.comWoodline Partners LP Cuts Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Woodline Partners LP trimmed its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 14.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,014,015 shares of the biopharmaceutical comMay 22, 2025 | marketbeat.comVestal Point Capital LP Acquires Shares of 305,000 Celldex Therapeutics, Inc. (NASDAQ:CLDX)Vestal Point Capital LP acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 305,000 shares of the biopharmaceMay 21, 2025 | marketbeat.comRafferty Asset Management LLC Acquires 61,464 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Rafferty Asset Management LLC boosted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 67.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 152,454 shareMay 21, 2025 | marketbeat.comBNP Paribas Financial Markets Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)BNP Paribas Financial Markets grew its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 122.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 62,631 shares of the biopharmaceutical company's stock after buying an additional 34,450 shareMay 21, 2025 | marketbeat.com29,480 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Bought by Tema Etfs LLCTema Etfs LLC purchased a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 29,480 shares of the biopharmaceutical company's stock, vMay 20, 2025 | marketbeat.com192,000 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Bought by TFG Asset Management GP LtdTFG Asset Management GP Ltd purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 192,000 shares of the biopharmaceutical company's stMay 20, 2025 | marketbeat.comSphera Funds Management LTD. Has $11.98 Million Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Sphera Funds Management LTD. increased its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 13.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 474,103 shares oMay 18, 2025 | marketbeat.comPoint72 Asset Management L.P. Acquires 847,264 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Point72 Asset Management L.P. lifted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 50.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,515,972 shares of the biopharmaceutiMay 18, 2025 | marketbeat.comPolar Asset Management Partners Inc. Grows Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Polar Asset Management Partners Inc. lifted its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 1,318.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 137,550 shares of the biopharmaceutical company's stock after purcMay 18, 2025 | marketbeat.comNorthern Trust Corp Raises Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Northern Trust Corp boosted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 6.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 597,605 shares of the biopharmaceutical company's stock after purchasingMay 18, 2025 | marketbeat.comPolar Capital Holdings Plc Cuts Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Polar Capital Holdings Plc lowered its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 42.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,565,831 shares of the biopharmaceutical company's stock aftMay 17, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 306,777 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)D. E. Shaw & Co. Inc. lessened its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 37.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 518,340 shares of the biopharmaceutical company's stock after selling 306,777 sharesMay 16, 2025 | marketbeat.comLeerink Partnrs Issues Pessimistic Outlook for CLDX EarningsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Equities research analysts at Leerink Partnrs decreased their FY2029 earnings estimates for Celldex Therapeutics in a research report issued on Friday, May 9th. Leerink Partnrs analyst T. Smith now anticipates that the biopharmaceutical comMay 14, 2025 | marketbeat.com2 'Strong Buy' Biotech Growth Stocks With Over 200% Upside PotentialMay 12, 2025 | msn.comCelldex Therapeutics: Promising Pipeline and Strategic Developments Justify Buy RatingMay 12, 2025 | tipranks.comCubist Systematic Strategies LLC Invests $3.91 Million in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Cubist Systematic Strategies LLC acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 154,512 shares of the biopharmaceutical company'sMay 12, 2025 | marketbeat.comFirst Trust Advisors LP Trims Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)First Trust Advisors LP decreased its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 50.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 18,372 shares of the biopharmaceutical company's stock after selling 19,071 shareMay 12, 2025 | marketbeat.comCelldex Therapeutics Q1 2025 Earnings: EPS of ($0. ...May 11, 2025 | gurufocus.comAlgert Global LLC Purchases 49,354 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Algert Global LLC increased its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 89.8% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 104,337 shares of the biopharmaceutical company's stock after buying an additional 49,3May 10, 2025 | marketbeat.comTudor Investment Corp ET AL Takes Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Tudor Investment Corp ET AL purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 32,545 shares of theMay 10, 2025 | marketbeat.comCelldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term GainMay 9, 2025 | insidermonkey.comDeep Track Capital LP Buys New Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Deep Track Capital LP purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,540,132 shares of the biopharmaceuticMay 9, 2025 | marketbeat.com Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDX Media Mentions By Week CLDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDX News Sentiment▼0.680.89▲Average Medical News Sentiment CLDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDX Articles This Week▼165▲CLDX Articles Average Week Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alkermes News BioCryst Pharmaceuticals News Ligand Pharmaceuticals News Amicus Therapeutics News Innoviva News MannKind News Dynavax Technologies News Novavax News OPKO Health News Geron News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLDX) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
